Imprimis Pharmaceuticals

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. Imprimis’ business is focused on its proprietary ophthalmology and urology drug formulations. The company’s pioneering ophthalmology formulation portfolio is disrupting the multi-billion dollar eye drop market, addressing patient compliance issues and providing other medical and economic benefits to patients. Imprimis launched its urology business in early 2015, which includes a patented formulation to address patients suffering from interstitial cystitis.
Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2012
Size (employees)
56 (est)
Imprimis Pharmaceuticals was founded in 2012 and is headquartered in San Diego, US

Imprimis Pharmaceuticals Office Locations

Imprimis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
350 12264 El Camino Real

Imprimis Pharmaceuticals Financials and Metrics

Imprimis Pharmaceuticals Financials

Imprimis Pharmaceuticals's revenue was reported to be $19.9 m in FY, 2016
USD

Revenue (Q3, 2017)

6.5 m

Gross profit (Q3, 2017)

3.1 m

Gross profit margin (Q3, 2017), %

48%

Net income (Q3, 2017)

(5.7 m)

EBIT (Q3, 2017)

(2.8 m)

Market capitalization (13-Dec-2017)

34.1 m

Cash (30-Sep-2017)

3.9 m
Imprimis Pharmaceuticals's current market capitalization is $34.1 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

1.7 m9.7 m19.9 m

Revenue growth, %

485%105%

Cost of goods sold

1.1 m5.2 m9.8 m

Gross profit

567.4 k4.5 m10.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

667.7 k441 k1.6 m2 m2.7 m4.4 m4.9 m4.9 m6.1 m6.9 m6.5 m

Cost of goods sold

239 k1 m1.1 m1.2 m2.2 m2.2 m2.3 m3.4 m3.3 m3.4 m

Gross profit

202.1 k556 k917 k1.5 m2.1 m2.7 m2.5 m2.7 m3.6 m3.1 m

Gross profit Margin, %

46%36%47%55%49%56%52%45%52%48%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.6 m8.2 m2.7 m8.9 m

Accounts Receivable

81.3 k840 k2.9 m

Inventories

105.1 k372.7 k1.4 m1.8 m

Current Assets

15.7 m9.1 m5.9 m14.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

16.8 m14.2 m12.1 m10.4 m2.9 m10.1 m6.6 m11.8 m5.4 m2.4 m7.4 m4.2 m3.9 m

Accounts Receivable

1.4 k81.1 k68.3 k436 k579 k701 k943 k1.9 m2.2 m3 m2.9 m2.6 m

Inventories

172.8 k351.2 k711 k793 k1.3 m1.2 m1.4 m1.9 m2 m1.8 m2.4 m

Current Assets

17.4 m14.4 m12.8 m11.3 m4.6 m12 m9.4 m14.9 m9.4 m9 m13.6 m10.4 m10.1 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (7.6 m)(10.1 m)(15.9 m)(19.1 m)

    Depreciation and Amortization

    5.7 k

    Accounts Receivable

    (22.9 k)(360 k)(2.1 m)

    Inventories

    (17 k)(159.5 k)(314 k)(429 k)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (2.1 m)(2.3 m)(2.6 m)(2.5 m)(3.1 m)(3.7 m)(4 m)(4.5 m)(4.6 m)(3.9 m)(5 m)(5.7 m)

    Depreciation and Amortization

    2.6 k

    Accounts Receivable

    (1.4 k)81.1 k68.3 k436 k579 k701 k943 k1.9 m2.2 m3 m2.6 m

    Inventories

    172.8 k351.2 k711 k793 k1.3 m1.2 m1.4 m1.9 m2 m2.4 m
      Y, 2017

      Financial Leverage

      7 x
      Show all financial metrics

      Imprimis Pharmaceuticals Market Value History

      Imprimis Pharmaceuticals's Web-traffic and Trends

      Imprimis Pharmaceuticals Online and Social Media Presence

      Imprimis Pharmaceuticals Company Life and Culture

      You may also be interested in